araag2/HINT huggingface dataset:
Clinical trial NCT01035983 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: frovatriptan 2.5 mg
SMILES: CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female aged 15 years and over (≥18 years in United Kingdom and South Africa), with at
             least a 12 month documented history of experiencing migraine according to IHS
             criteria, including confirmation of a 3 month diary based documented history of MAM.

          -  An average frequency of MAM in at least two out of three menstrual cycles, within the
             previous 12 months

          -  Regular, predictable menstrual periods

          -  MAM headaches occurring between Day -2 and day +4 of menses

          -  Able and willing to sign informed consent and to comply with study procedures,
             including completion of the diary cards.

        Exclusion Criteria:

          -  More than three migraine attacks per month that were not MAM attacks

          -  A history of myocardial infarction, ischemic heart disease (or presenting with
             symptoms or signs compatible with ischemic heart disease), coronary vasospasm or
             peripheral vascular disease

          -  Significant cerebrovascular disease including basilar or hemiplegic migraine

          -  Uncontrolled hypertension (SBP >180 mmHg, DBP >95 mmHg)

          -  Severe hepatic or renal insufficiency

          -  More than 15 headache days per month, exclusive of migraine headache

          -  Any other condition or serious illness which, in the opinion of the investigator,
             would interfere with optimal participation in the study

          -  A history of clinically relevant allergy, including that to frovatriptan or other
             triptans

          -  Pregnant or breast-feeding, or intending to become pregnant or breast-feed during the
             study period (patients were to be using adequate contraception and have a negative
             pregnancy test at screening)

          -  Treatment with another investigational drug within 30 days or 5 half-lives (whichever
             was longer) before the screening visit

          -  Any change in their oral contraceptive medication (if applicable) in the 2 months
             prior to screening, or anticipation of any change during study participation

          -  Any change in the type or dose of any prophylactic migraine medication in the 2 months
             prior to screening, or anticipation of any change during study participation

          -  A history of migraine with aura, according to IHS criteria, and currently treated with
             a combined oral contraceptive (South Africa only).
Clinical trial NCT00423605 (phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: xyrem®
SMILES: [Na+].OCCCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has qualified for and completed either study 06-009 (NCT00423813) or 06-008
             (NCT00371137).

          -  Subject is able, in the opinion of the investigator, to take Xyrem® for approximately
             9-1/2 months.

        Exclusion Criteria:

          -  Subject terminated early from either study 06-009 or 06-008.

          -  Subject experienced any serious adverse event related to study drug in either study
             06-009 or 06-008.

          -  Subject, in the opinion of the investigator, experienced an adverse event in 06-009 or
             06-008 that may prevent him/her from safely participating in this study.
Clinical trial NCT00095134 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: risperidone
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Understand and sign the informed consent form

          -  Age 18-65

          -  Healthy on the basis of Physical Exam

          -  Treatment with a single antidepressant 4 weeks prior to study start and willingness to
             maintain on stable dose of the same antidepressant throughout the study

          -  Current diagnosis of Major Depressive Disorder

          -  Judgement of the clinician that the subject has shown a sub-optimal response to the
             antidepressant

        Exclusion Criteria:

          -  Presence of other serious medical illness(es)
Clinical trial NCT00361335 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: golimumab, methotrexate, placebo
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        - Must have a diagnosis of active rheumatoid arthritis (RA) (according to the revised 1987
        criteria of the ARA (American Rheumatism Association) with at least 4 swollen and 4 tender
        joints for at least 3 months prior to screening - Have been treated with and tolerated
        methotrexate (MTX) at a dose of at least 15 mg per week for at least 3 months prior to
        screening - Have been on a stable MTX dose of greater than or equal to 15 mg per week and
        less than or eual to 25 mg per week for at least 4 weeks prior to screening - If using non
        steroidal anti-inflammatory agents (such as naproxen) or other pain relievers for RA, must
        be on a stable dose for at least 2 weeks prior to the first administration of study agent

        Exclusion Criteria:

        - Participants having known hypersensitivity (severe allergy) to human immunoglobulin
        proteins or other components of golimumab - Having known clinically serious adverse
        reaction to a biologic anti-TNF agent - Have had history of latent or active granulomatous
        infection, including tuberculosis, histoplasmosis, or coccidioidomycosis, prior to
        screening
Clinical trial NCT00412984 (phase 3, status: completed)
Conditions: atrial fibrillation, atrial flutter
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20, I48.3, I48.4, I48.92
Drugs: warfarin, apixaban
SMILES: S1SSSSSSS1, COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females ≥ 18 yrs with atrial fibrillation (AF) and one or more of the
             following risk factors for stroke:

          -  Age ≥ 75, previous stroke

          -  transient ischemic attack (TIA) or Systemic Embolism (SE)

          -  Symptomatic congestive heart failure or left ventricular dysfunction with left
             ventricular ejection fraction (LVEF) ≤ 40%

          -  Diabetes mellitus or hypertension requiring pharmacological treatment
Clinical trial NCT00237809 (phase 3, status: completed)
Conditions: schizophrenia, schizoaffective disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F25.9, F25.0, F25.1, F25.8
Drugs: d-serine, placebo
SMILES: N[C@H](CO)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of schizophrenia or schizoaffective disorder

        Exclusion

          -  Pregnant or lactating
Clinical trial NCT00404820 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: zoledronic acid 5 mg solution, alendronate 70 mg tablets, calcium/vitamin d
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

        - Low bone mineral density (as indicated by a "t-score" of -2.0 or lower) postmenopausal
        women

        Exclusion Criteria:

        - Previous use of oral and iv bisphosphonates, parathormone, strontium ranelate, sodium
        fluoride.

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT00175019 (phase 3, status: completed)
Conditions: gout
ICD codes: M10.9, M10.08, M10.00, M10.011, M10.012, M10.019, M10.021
Drugs: febuxostat, febuxostat, allopurinol
SMILES: CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N, CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N, O=C1N=CN=C2NNC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Is receiving thiazide diuretic therapy (only to subjects randomized to or receiving
             febuxostat).

          -  Has a serum urate level less than 8.0 mg/dL and is not taking uric acid-lowering
             therapy (other than allopurinol or febuxostat).

          -  Has participated in a clinical study in which febuxostat was administered.

          -  Is completing Phase 3 Studies C02-009 or C02-010.

          -  Must not have experienced any serious study drug-related adverse events in the
             previous study.

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study

        Exclusion Criteria:

          -  Has had any other significant medical condition as defined by the investigator that
             would interfere with the treatment, safety, or compliance with the protocol.

          -  Is intolerant of allopurinol.
Clinical trial NCT01189487 (phase 3, status: completed)
Conditions: pneumonia, bacterial
ICD codes: J15.9, P23.6
Drugs: ampicillin sodium/sulbactam sodium
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  16 years of age or older.

          -  Patients who were diagnosed as moderate to severe community acquired pneumonia
             requiring initial intravenous therapy and hospitalization.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity or intolerance to ampicillin sodium/sulbactam
             sodium, other penicillins, or cephems.

          -  Hepatic dysfunction [Aspartate Aminotransferase(AST), Alanine Aminotransferase (ALT),
             total bilirubin > 3 times upper limit of normal range values].

          -  Severe renal dysfunction (creatinine clearance < 30 ml/min).

          -  Severe underlying disease; patients in which drug clinical evaluation is difficult
             because of confounding diseases.
Clinical trial NCT00580216 (phase 3, status: terminated)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: idrabiotaparinux sodium, warfarin, placebo (for idrabiotaparinux), placebo (for warfarin), avidin, placebo (for avidin)
SMILES: S1SSSSSSS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    early discontinuation based on strategic sponsor decision not driven by any safety concern
  
Eligibility criteria:

        Inclusion Criteria:

          -  Non valvular atrial fibrillation (AF)

          -  Indication for long-term Vitamin-K antagonist (VKA) therapy based on the presence of
             previous ischemic stroke, transient ischemic attack (TIA) or systemic embolism and/or
             at least two of the following risk factors: hypertension requiring drug treatment,
             moderately or severely impaired left ventricular function and/or congestive heart
             failure, age > or = 75 years, diabetes mellitus.

        Main exclusion Criteria:

          -  Indication for VKA other than AF

          -  Stroke or TIA within previous 5 days

          -  Transient AF caused by a reversible disorder

          -  Planned major surgery/trauma or cardioversion within 30 days

          -  INR > 3 at baseline

          -  Active bleeding or high risk of bleeding

          -  Uncontrolled hypertension

          -  Pregnancy or childbearing potential without proper contraceptive measures or breast
             feeding.
Clinical trial NCT00120770 (phase 3, status: terminated)
Conditions: hiv infections, gonorrhea, chlamydia infections
ICD codes: Z21
Drugs: cellulose sulfate vaginal gel (microbicide)
SMILES: OC(=O)CC(O)(CC(O)=O)C(O)=O
Reason stopped: 
    the study was halted in january 2007 due to safety concerns.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to give informed consent

          -  At least 18 years old and not more than 35 years old

          -  Average of three vaginal coital acts per week with a male partner

          -  More than one male sexual partner in the last 3 months

          -  Willing to use study product as directed

          -  Willing to adhere to follow-up schedule

          -  Willing to participate in the study for 12 months

          -  Willing to report self-medication during study participation

          -  Willing to give urine for pregnancy testing; self-administered vaginal swabs for GC/CT
             testing; OMT for HIV monthly; finger prick for HIV confirmation if required; and blood
             draw for syphilis and HIV at baseline, and for HIV at the final visit

          -  Willing to not use a spermicide, other vaginal contraceptive, or vaginal lubricant
             during the study

          -  At least 3 months since end of the last pregnancy

        Exclusion Criteria:

          -  History of adverse reactions to the study products, including latex

          -  Pregnant or desire a pregnancy during the 12 months of participation

          -  Injection drug user

          -  Gynecological abnormality that may have an impact on the safety and/or response to the
             study gel according to the investigator

          -  HIV positive as diagnosed by OraQuick® rapid test

          -  Participation in any other microbicide research

          -  Discontinued from the CS study previously

          -  Any condition (social or medical) which, in the opinion of the investigator, would
             make study participation unsafe or complicate data interpretation
Clinical trial NCT01313650 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: 62.5/25mcg, 62.5mcg, 25mcg, placebo
SMILES: OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of COPD

          -  10 pack-year or greater history of cigarette smoking

          -  Post-bronchodilator FEV1/FVC of <0.7

          -  Predicted FEV1 of 70% of normal or less

          -  Modified Medical Research Council (mMRC) dyspnea score of 2 or greater

        Exclusion Criteria:

          -  Women who are pregnant, lactating, or planning to become pregnant

          -  Respiratory disorders other than COPD, including a current diagnosis of asthma

          -  Clinically significant non-respiratory diseases or abnormalities that are not adequate
             controlled

          -  Significant allergy or hypersensitivity to anticholinergics, beta-agonist, or the
             excipients of magnesium stereate or lactose used in the inhaler delivery device

          -  Hospitalization for COPD or pneumonia within 12 weeks prior to screening

          -  Lung volume reduction surgery within 12 weeks prior to screening

          -  Abnormal and clinically significant ECG findings at screening

          -  Clinically significant laboratory findings at screening

          -  Use of systemic corticosteroids, antibiotics for respiratory tract infections, strong
             cytochrome P450 3A4 inhibitors, high dose inhaled steroids (>1000mcg fluticasone
             propionate or equivalent), PDE4 inhibitors, tiotropium, oral beta2-agoinists, short-
             and long-acting inhaled beta2-agonists, ipratropium, inhaled sodium cromoglycate or
             nedocromil sodium, or investigational medicines for defined time periods prior to the
             screening visit

          -  Use of long-term oxygen therapy (12 hours or greater per day)

          -  Regular use of nebulized treatment with short-acting bronchodilators

          -  Participation in the acute phase of a pulmonary rehabilitation program

          -  A know or suspected history of alcohol or drug abuse

          -  Affiliation with the investigational site

          -  Previous use of GSK573719 or GW642444 alone or in combination, including the
             combination of fluticasone furoate and GW64244
Clinical trial NCT00225862 (phase 3, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: ropinirole
SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
Eligibility criteria:

        Â Inclusion criteria:

          -  Patients diagnosed with Restless Legs Syndrome (RLS).

          -  Patients diagnosed with RLS (symptoms include an overwhelming urge to move legs
             usually accompanied by uncomfortable sensations in the legs; usually occur at rest;
             worse during the evening or night and generally relieved, at least temporarily, by
             movement).

          -  Patients must give written informed consent prior to any specific study procedures.

        Exclusion criteria:

          -  Patients with a primary sleep disorder other than RLS.

          -  Patients with symptoms of secondary RLS (i.e., renal failure, iron deficient anemia,
             pregnancy) or other movement disorders (i.e., Parkinson's Disease).

          -  Other inclusion or exclusion criteria to be evaluated by the physician.
Clinical trial NCT00386139 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: aliskiren/hctz
SMILES: NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatients 18 years old or older.

          -  Patients with a diagnosis of hypertension.

          -  Patients who are eligible and consent to participate in the study

        Exclusion Criteria:

          -  Severe hypertension

          -  Previous or current diagnosis of heart failure.

          -  History of hypertensive encephalopathy or cerebrovascular accident, transient ischemic
             cerebral attack (TIA), myocardial infarction, coronary bypass surgery, or any
             percutaneous coronary intervention (PCI).

          -  Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01645124 (phase 3, status: terminated)
Conditions: polycythemia vera
ICD codes: D45
Drugs: hydroxyurea
SMILES: NC(=O)NO
Reason stopped: 
    low accrual rate not allowing planned sample size leads to a futility condition
  
Eligibility criteria:

        Inclusion Criteria:

        Males and females aged 18 years or more are eligible for the study if they meet all the
        following inclusion criteria:

          -  New diagnosis of PV according to WHO 2007 diagnostic criteria including Jak 2 V617F
             mutation status;

          -  Old diagnosis of PV confirmed with JAK-2 positivity and clinical course of the
             disease;

          -  Ability and willingness to comply with all study requirements;

          -  Written informed consent (obtained before any study specific procedure).

        Exclusion Criteria:

          -  Pregnant or lactating women or women of childbearing potential who are not protected
             from pregnancy by an accepted method of contraception;

          -  Known hypersensitivity or contraindication to study treatments;

          -  Significant liver (AST or ALT > 2.5 times ULN) or renal disease (creatinine > 2
             mg/ml);

          -  Presence of any life-threatening condition or of any disease (e.g. cancer) that is
             likely to significantly shorten life expectancy;

          -  History of active substance or alcohol abuse within the last year;

          -  Any condition that in the opinion of the investigator would jeopardize the evaluation
             of efficacy or safety or be associated with poor adherence to the protocol - Baseline
             and FUP visits schedule and assessments

          -  Logistic problem related to the patient.
Clinical trial NCT00314210 (phase 3, status: completed)
Conditions: anxiety disorders
ICD codes: F41.1, F41.9, F40.9, F43.22, F41.0, F93.0, F12.980
Drugs: quetiapine sr
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patients will be male or female, 18 to 65 years of age (inclusive), with a diagnosis
             of GAD according to DSM-IV criteria 300.02 as assessed by the MINI.

        Exclusion Criteria:

          -  Patients suffering from depressive symptoms, defined as having a Montgomery-Åsberg
             Depression Rating Scale (MADRS) total score of 17 or more at the enrolment visit, will
             be excluded from participation in this study.
Clinical trial NCT01341782 (phase 3, status: completed)
Conditions: secondary hyperparathyroidism, hemodialysis
ICD codes: E21.1, N25.81, I95.3, R88.0, Z49.31
Drugs: paricalcitol, maxacalcitol, paricalcitol placebo, maxacalcitol placebo
SMILES: CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, [H]\C(\C(\[H])=C1/CCC[C@@]2(C)[C@@]1([H])CC[C@]2([H])[C@]([H])(C)OCCC(C)(C)O)=C1/C[C@@]([H])(O)C[C@]([H])(O)C1=C, CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, [H]\C(\C(\[H])=C1/CCC[C@@]2(C)[C@@]1([H])CC[C@]2([H])[C@]([H])(C)OCCC(C)(C)O)=C1/C[C@@]([H])(O)C[C@]([H])(O)C1=C
Eligibility criteria:

        Inclusion Criteria:

          -  Adult Chronic Kidney Disease (CKD) Stage 5 patients undergoing dialysis with stable
             dialysate calcium and phosphate binders

          -  On three times weekly hemodialysis for at least 3 months prior with intact parathyroid
             hormone (iPTH) greater than or equal to 300 pg/mL, adjusted normalized serum total
             calcium (Ca) greater than or equal to 8.4 to less than 10.2 mg/dL, serum phosphorus
             (P) less than or equal to 6.5 mg/dL.

        Exclusion Criteria:

          -  Patients with a recent history of severe cardiovascular or hepatic disease,
             uncontrolled hypertension or uncontrolled diabetes

          -  Patients who have received a parathyroidectomy or ethanol infusion within the prior
             year

          -  Patients taking drugs that affect iPTH, calcium or bone metabolism

          -  Patients who will need to take chronic doses (greater than or equal to 2 consecutive
             weeks) of cytochrome P450 inhibitors (e.g., clarithromycin, grapefruit products) or
             inducers (e.g., carbamazepine, rifampicin)

          -  Female patients who are pregnant, possibly pregnant, wish to become pregnant, or
             participate in breastfeeding during the study period.
Clinical trial NCT02118896 (phase 3, status: completed)
Conditions: heart transplantation, liver transplantation, kidney transplantation
ICD codes: M31.11, Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0, N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: fk506e
SMILES: CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who had already participated in the previous phase II pharmacokinetic or
             phase III studies with FK506E (MR4).

          -  Patients capable of understanding the purpose and risks of the study, who had been
             fully informed and given written informed consent to participate in the study.

        Exclusion Criteria:

          -  Pregnant women or nursing mothers.

          -  Women unwilling or unable to use adequate contraception during the study.